Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Lymphoma Therapeutics Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Targeted Therapy
  • 1.4.3 Approved Drugs
  • 1.4.4 Pipeline Drugs
  • 1.4.5 Chemotherapy
  • 1.4.6 Approved Drugs
  • 1.4.7 Pipeline Drugs
  • 1.4.8 Immunotherapy
• 1.5 Market by Application
  • 1.5.1 Global Lymphoma Therapeutics Market Share by Application (2014-2025)
  • 1.5.2 Hodgkin Lymphoma
  • 1.5.3 Non-Hodgkin Lymphoma
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Lymphoma Therapeutics Market Size
• 2.2 Lymphoma Therapeutics Growth Trends by Regions
  • 2.2.1 Lymphoma Therapeutics Market Size by Regions (2014-2025)
  • 2.2.2 Lymphoma Therapeutics Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Lymphoma Therapeutics Market Size by Manufacturers
  • 3.1.1 Global Lymphoma Therapeutics Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Lymphoma Therapeutics Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Lymphoma Therapeutics Market Concentration Ratio (CR5 and HHI)
• 3.2 Lymphoma Therapeutics Key Players Head office and Area Served
• 3.3 Key Players Lymphoma Therapeutics Product/Solution/Service
• 3.4 Date of Enter into Lymphoma Therapeutics Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Lymphoma Therapeutics Market Size by Type (2014-2019)
• 4.2 Global Lymphoma Therapeutics Market Size by Application (2014-2019)

5 United States

• 5.1 United States Lymphoma Therapeutics Market Size (2014-2019)
• 5.2 Lymphoma Therapeutics Key Players in United States
• 5.3 United States Lymphoma Therapeutics Market Size by Type
• 5.4 United States Lymphoma Therapeutics Market Size by Application

6 Europe

• 6.1 Europe Lymphoma Therapeutics Market Size (2014-2019)
• 6.2 Lymphoma Therapeutics Key Players in Europe
• 6.3 Europe Lymphoma Therapeutics Market Size by Type
• 6.4 Europe Lymphoma Therapeutics Market Size by Application

7 China

• 7.1 China Lymphoma Therapeutics Market Size (2014-2019)
• 7.2 Lymphoma Therapeutics Key Players in China
• 7.3 China Lymphoma Therapeutics Market Size by Type
• 7.4 China Lymphoma Therapeutics Market Size by Application

8 Japan

• 8.1 Japan Lymphoma Therapeutics Market Size (2014-2019)
• 8.2 Lymphoma Therapeutics Key Players in Japan
• 8.3 Japan Lymphoma Therapeutics Market Size by Type
• 8.4 Japan Lymphoma Therapeutics Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Lymphoma Therapeutics Market Size (2014-2019)
• 9.2 Lymphoma Therapeutics Key Players in Southeast Asia
• 9.3 Southeast Asia Lymphoma Therapeutics Market Size by Type
• 9.4 Southeast Asia Lymphoma Therapeutics Market Size by Application

10 India

• 10.1 India Lymphoma Therapeutics Market Size (2014-2019)
• 10.2 Lymphoma Therapeutics Key Players in India
• 10.3 India Lymphoma Therapeutics Market Size by Type
• 10.4 India Lymphoma Therapeutics Market Size by Application

11 Central & South America

• 11.1 Central & South America Lymphoma Therapeutics Market Size (2014-2019)
• 11.2 Lymphoma Therapeutics Key Players in Central & South America
• 11.3 Central & South America Lymphoma Therapeutics Market Size by Type
• 11.4 Central & South America Lymphoma Therapeutics Market Size by Application

12 International Players Profiles

• 12.1 F. Hoffmann-La Roche AG
  • 12.1.1 F. Hoffmann-La Roche AG Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Lymphoma Therapeutics Introduction
  • 12.1.4 F. Hoffmann-La Roche AG Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.1.5 F. Hoffmann-La Roche AG Recent Development
• 12.2 Eli Lilly
  • 12.2.1 Eli Lilly Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Lymphoma Therapeutics Introduction
  • 12.2.4 Eli Lilly Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.2.5 Eli Lilly Recent Development
• 12.3 Pfizer Inc.
  • 12.3.1 Pfizer Inc. Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Lymphoma Therapeutics Introduction
  • 12.3.4 Pfizer Inc. Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.3.5 Pfizer Inc. Recent Development
• 12.4 Bristol-Myers Squibb (BMS)
  • 12.4.1 Bristol-Myers Squibb (BMS) Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Lymphoma Therapeutics Introduction
  • 12.4.4 Bristol-Myers Squibb (BMS) Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.4.5 Bristol-Myers Squibb (BMS) Recent Development
• 12.5 Celgene Corp.
  • 12.5.1 Celgene Corp. Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Lymphoma Therapeutics Introduction
  • 12.5.4 Celgene Corp. Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.5.5 Celgene Corp. Recent Development
• 12.6 GlaxoSmithKline
  • 12.6.1 GlaxoSmithKline Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Lymphoma Therapeutics Introduction
  • 12.6.4 GlaxoSmithKline Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.6.5 GlaxoSmithKline Recent Development
• 12.7 Accredo Health Group
  • 12.7.1 Accredo Health Group Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Lymphoma Therapeutics Introduction
  • 12.7.4 Accredo Health Group Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.7.5 Accredo Health Group Recent Development
• 12.8 Baxter International
  • 12.8.1 Baxter International Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Lymphoma Therapeutics Introduction
  • 12.8.4 Baxter International Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.8.5 Baxter International Recent Development
• 12.9 Eisai Pharmaceuticals
  • 12.9.1 Eisai Pharmaceuticals Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Lymphoma Therapeutics Introduction
  • 12.9.4 Eisai Pharmaceuticals Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.9.5 Eisai Pharmaceuticals Recent Development
• 12.10 Genelabs Technologies
  • 12.10.1 Genelabs Technologies Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Lymphoma Therapeutics Introduction
  • 12.10.4 Genelabs Technologies Revenue in Lymphoma Therapeutics Business (2014-2019)
  • 12.10.5 Genelabs Technologies Recent Development
• 12.11 Merck & Co.

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the body. When you have lymphoma, lymphocytes change and grow out of control. Lymphoma comprises of a diverse group of blood cancers with different causes and treatment pathways. It is mainly categorized into two forms i.e., Hodgkin Lymphoma and non-Hodgkin Lymphoma (NHL).
In 2018, the global Lymphoma Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Lymphoma Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Lymphoma Therapeutics development in United States, Europe and China.

The key players covered in this study
F. Hoffmann-La Roche AG
Eli Lilly
Pfizer Inc.
Bristol-Myers Squibb (BMS)
Celgene Corp.
GlaxoSmithKline
Accredo Health Group
Baxter International
Eisai Pharmaceuticals
Genelabs Technologies
Merck & Co.

Market segment by Type, the product can be split into
Targeted Therapy
Approved Drugs
Pipeline Drugs
Chemotherapy
Approved Drugs
Pipeline Drugs
Immunotherapy

Market segment by Application, split into
Hodgkin Lymphoma
Non-Hodgkin Lymphoma

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Lymphoma Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Lymphoma Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Lymphoma Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.